Skip to main navigation
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Investors

Press Releases

Date
Latest Press Release

May 11, 2023

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

April 13, 2023

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments

March 16, 2023

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 8, 2023

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

December 15, 2022

Eiger BioPharmaceuticals Announces Leadership Change

December 8, 2022

Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

December 7, 2022

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

November 8, 2022

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

November 3, 2022

Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Contact Us
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX

Contact Us

Eiger Logo

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX